Kainos Laboratories

Kainos Laboratories FCF per Share

Delisted

The Free Cash Flow per Share of Kainos Laboratories (4556.T) as of Oct 29, 2026 is 148.93 JPY. In the previous year, Free Cash Flow per Share was 84.69 JPY — a change of 75.85% (higher).

FCF per Share

148.93JPY

YoY

75.85%

Last updated:

Free Cash Flow per Share of Kainos Laboratories is 2025 148.93 JPY. Free Cash Flow per Share of Kainos Laboratories was 2024 84.69 JPY. It decreases by 75.85% higher compared to the previous year.

The Kainos Laboratories FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
39.86 JPY
Jan 1, 2019
76.20 JPY
Jan 1, 2020
151.77 JPY
Jan 1, 2021
124.90 JPY
Jan 1, 2022
114.26 JPY
Jan 1, 2023
128.61 JPY
Jan 1, 2024
84.69 JPY
Jan 1, 2025
148.93 JPY
The Kainos Laboratories FCF per Share history
YEARFCF per ShareYoY
148.93JPY+75.85%
84.69JPY-34.15%
128.61JPY+12.56%
114.26JPY-8.51%
124.90JPY-17.71%
151.77JPY+99.17%
76.20JPY+91.15%
39.86JPY-45.05%
72.54JPY+123.25%
32.49JPY-58.99%
79.23JPY+3.65%
76.44JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

Free Cash Flow per Share of Kainos Laboratories is 148.93 JPY in 2025.

Free Cash Flow per Share of Kainos Laboratories changed from 84.69 JPY to 148.93 JPY, representing a 75.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Kainos Laboratories

All Key Metrics — Kainos Laboratories